Milk Fat Globule Membrane (MFGM) in Infant Formula: Structure, Benefits, and Safety

Structure and Composition

MFGM is a triple‑layered phospholipid membrane that naturally surrounds fat droplets in human milk and is added to some infant formulas to more closely mimic breast‑milk structure and to provide neurocognitive and immune benefits. 1, 2
The membrane comprises three distinct layers:
- Inner layer – proteins embedded within the phospholipid matrix. 3
- Intermediate layer – a phospholipid triple‑membrane structure. 3
- Outer layer – high‑molecular‑weight glycoproteins together with sphingomyelin/cholesterol complexes. 4, 5
In native breast milk, MFGM‑coated fat globules have an average diameter of 3–5 µm, whereas conventional infant formulas contain protein‑coated fat droplets < 0.5 µm that lack a membrane coating. 6, 5

Adding MFGM to formula promotes a digestion process that more closely resembles human milk by enhancing lipolysis through digestive lipases and bile salts; this is especially important because infants have relatively low pancreatic lipase and bile‑salt concentrations. Evidence from randomized trials supports this mechanistic benefit. 1, 7

Indonesian infants (started before 8 weeks of age and fed until 6 months) receiving MFGM‑supplemented formula showed higher general IQ, improved hand‑eye coordination, and better performance on the Griffiths developmental scale at 24 weeks compared with non‑supplemented formula. Randomized controlled trial evidence. 1, 6
Swedish infants (2–6 months old) fed a formula containing Lacprodan MFGM‑10 achieved higher Bayley‑III cognitive scores at 12 months. Randomized controlled trial evidence. 1, 6
The COGNIS study reported fewer behavioral problems up to 2.5 years of age in children who received MFGM‑enriched formula versus standard formula. Randomized controlled trial evidence. 1, 6
The underlying mechanism is attributed to sphingolipids and phospholipids in MFGM, which are essential for brain myelination, neuronal growth, migration, and maturation. 8

A double‑blind, randomized controlled trial in Sweden (160 formula‑fed infants, 80 breast‑fed reference) demonstrated that protein‑rich MFGM given from 2 to 6 months significantly reduced infectious morbidity through 6 months of age. Specific outcomes included:
- Lower incidence of acute otitis media. 1
- Reduced use of antipyretic medication. 6
- Decreased serum IgG concentrations against pneumococcal antigens after vaccination. 1, 7

MFGM supplementation does not adversely affect growth; weight gain was comparable between infants receiving lipid‑rich versus protein‑rich MFGM fractions. Randomized controlled trial evidence. 1, 6

Commercially available MFGM can be derived from:
- Buttermilk‑based ingredients. 1
- Milk cream. 1
- Bovine MFGM concentrates such as Lacprodan MFGM‑10, the first MFGM ingredient introduced to the global infant‑formula market. 1, 6
Incorporation of MFGM improves the triacylglycerol structure of formula (e.g., increased sn‑2 palmitate) and enhances fat‑emulsion composition and ultrastructure, rendering the product more similar to human milk in both structure and function. Evidence from formulation studies. 7